Search

Objective: To prepare iodine-131( 131 I) labeled biodegradable microspheres with chitosan and collagen for treating liver cancer., Methods: Collagen-chitosan microspheres (CCMSs) were prepared with type-Ⅰ collagen and chitosan using emulsification-chemical cross-linking method. The size of the CCMSs were determined by electron microscope. 131 I-CCMSs were achieved using Chloramine-T. The labelling rate of 131 I was recorded. The stability of 131 I-CCMSs in vitro were evaluated in PBS or human blood serum through 192 h incubation. The HepG2 model was established in nude mice 28 d after subcutaneous injection of 10 6 HepG2 cells. The model mice were sacrificed 7 d after injection of 131 I-CCMSs,blank microspheres,or PBS (five mice in each group) into the HepG2 tumor xenografts. Samples of various organs were collected to determine the distribution of 131 I-CCMSs. The curative effect of 131 I-CCMSs on liver cancer was assessed by staining with HE for histological analyses., Results: CCMSs were synthesized with a smooth and spherical shape and an average diameter of (5.1±1.2) μm. A radiolabeling rate of 86.10% was achieved. 131 I radio-loading remained stable: 92.00% in saline and 83.00% in human serum after 192 h incubation. 131 I was mainly concentrated in the subcutaneous tumor tissues. Potent curative effects of 131 I-CCMSs on subcutaneous tumor tissues were demonstrated., Conclusion: Biodegradable CCMSs were successfully prepared and radiolabeled. The 131 I-CCMSs exhibited potential curative effects on liver cancer,with high stability in vitro and in vivo., (CopyrightCopyright© by Editorial Board of Journal of Sichuan University (Medical Science Edition).)

Objectives: To establish a mouse model bearing human prostate cancer xenograft with bone metastasis by the monitoring with X-Ray, Micro CT, and ¹⁸F-NaF PET/CT., Methods: Sixteen male Balb/c nude mice were allocated into control (6 mice) and experimental group (10 mice). In experimental group, the mice were subjected to percutaneous injection of 2×10 5 PC-3 cells into tibial plateau, bone defects were assessed after 21 d by X-ray, Micro-CT and ¹⁸F-NaF PET/CT, and bone damages were evaluated by HE staining. In control group, equal volume of saline was injected into the mice., Results: At 21 d post modeling, the significant radioactive ¹⁸F--NaF signals were found in the tibial intramedullary cavity of all 10 mice in experimental group. The ROI value evaluation showed that SUV max in control group was 0.62±0.14, but SUV max in tumor group was 2.10±0.13, which indicated abnormal bone metabolism. The serum alkaline phosphate level and HE staining results also confirmed that tumor mediated bone destruction and osteogenesis. However, X-ray and Micro-CT did not indicate precise diagnostic bone defect., Conclusion: Bone metastasis model of prostate PC-3 cancer cells were successfully established by intratibial injection. ¹⁸F-NaF PET/CT could detect tumor invasion and bone osteogenesis in the early stage of modeling.

Objective: To synthesize and study the specific binding affinity of tumor-penetrating peptide YCCS to non-small cell lung carcinoma (NSCLC) cells in vitro., Methods: YCCS peptide was designed by fusing the neuropilin-1 (NRP-1) binding sequence and NSCLC binding peptide CS. YCCS peptide was synthesized and fluorescent labeled with N-terminal FITC. NRP-1 positive human NSCLC cell A549, NRP-1 positive human breast cancer cell MDA-MB-231, normal human bronchial epithelium HBE135-E6E7 and human liver cell HL-7702 were incubated respectively, then we observed the specific binding affinity of tumor-penetrating peptide YCCS to NSCLC cells., Results: After treated with 5 μmol/L peptide, significant fluorescent signals of FITC-YCCS peptide were demonstrated only in NSCLC A549 cells but marginal captured signal in MDA-MB-231, normal human HBE135-E6E7 or HL-7702 cells, which revealed specific NSCLC cells binding affinity. In 20 μmol/L treated group, non-specific binding were found in MDA-MB-231 and HL-7702 cells., Conclusion: The results of this novel designed YCCS peptide indicated a promising strategy for improving tumor penetrating with delivery capability of drugs to NSCLC A549 cells when treated with 5 μmol/L peptide.